## Saturday 30 April 2016

### Teaching Lecture
- **Technology assessment**
- **CRISP/CAIC technology: from cells to mice to stem cell therapy**
- **Partial breast irradiation: who, when and how?**
- **TBC**
- **Role of brachytherapy in the management of gynaecologic tumours**
- **Challenges in MR guidance**
- **Patient specific quality assurance in proton therapy**
- **Side effects - actual clinical benefit in particular considerations, from photons to protons**

### Symposium
- **Selection of patients for proton therapy**
  - Mitigating normal tissue toxicity
  - Proton vs. heavy ions: advantages and disadvantages
  - Physical advantages of particles: protons vs. heavy ions
  - How strong is the current clinical evidence for proton therapy?
  - A physicist's view
  - A clinician's view

- **Regional nodal irradiation for breast cancer**
  - The role of surgery, neo-adjuvant therapy?
  - The internal mammary chain - should we treat it in every node-positive patient?
  - Tumour targeting - considering normal tissue toxicity in the setting of local recurrence
  - Tumour - normal tissue models for treatment planning: the clinical perspective

- **Assessment and management of rectal morbidity**
  - MRI: a new era for clinical SABR
  - Protons or heavy ions?
  - The role of imaging in active surveillance for prostate cancer
  - Tumour - normal tissue models for treatment planning: the clinical perspective

- **Towards user-oriented QA procedures for treatment verification**
  - How to use MR-PET for radiation oncology
  - Technology assessment

- **Robust and accurate functional MRI for radiotherapy**
  - MR-PET: a new era for clinical SABR
  - Protons or heavy ions?

- **Joint ESTRO - SAE offers on dosimetry, QA and audit for advanced treatment techniques**
  - New code of practice for small and non-standard fields
  - Which accuracy considerations in small fields are clinically acceptable for SABR/SNAD?

- **Strategies for treatment planning**
  - New code of practice for small and non-standard fields
  - Auto-planning: consequences for the department

### Proffered Papers
- **Selection of patients for proton therapy**
- **Regional nodal irradiation for breast cancer**
- **Assessment and management of rectal morbidity**
- **Towards user-oriented QA procedures for treatment verification**
- **Robust and accurate functional MRI for radiotherapy**
- **Joint ESTRO - SAE offers on dosimetry, QA and audit for advanced treatment techniques**
- **Strategies for treatment planning**

### Poster Viewing
- **Selection of patients for proton therapy**
- **Regional nodal irradiation for breast cancer**
- **Assessment and management of rectal morbidity**
- **Towards user-oriented QA procedures for treatment verification**
- **Robust and accurate functional MRI for radiotherapy**
- **Joint ESTRO - SAE offers on dosimetry, QA and audit for advanced treatment techniques**
- **Strategies for treatment planning**

---

### Key Dates
- **08:00 - 08:40**
  - TEACHING LECTURE
  - CRISP/CAIC technology: from cells to mice to stem cell therapy
  - Partial breast irradiation: who, when and how?
  - TBC
  - Role of brachytherapy in the management of gynaecologic tumours
  - Challenges in MR guidance
  - Patient specific quality assurance in proton therapy
  - Side effects - actual clinical benefit in particular considerations, from photons to protons

- **08:45 - 10:00**
  - SYMPOSIUM
  - Mitigating normal tissue toxicity
  - Mitigation of radiation-induced skin reactions
  - Assessment and management of rectal morbidity
  - Tumour - normal tissue models for treatment planning: the clinical perspective

- **10:00 - 10:30**
  - COFFEE BREAK

- **10:30 - 11:10**
  - PROFFERED PAPERS

- **11:10 - 12:10**
  - PRESENTING SYMPOSIUM

- **12:20 - 13:20**
  - WHO'S WHO'S WHO: BRENN ANNUAL LECTURE

- **15:00 - 15:45**
  - SYMPOSIUM
  - Hot topics in SABR: time for randomised clinical trials?
  - Proton or heavy ions?
  - Proton vs. heavy ions: advantages and disadvantages

- **15:45 - 16:25**
  - DEBATE

- **16:25 - 17:05**
  - COFFEE BREAK

- **17:05 - 17:15**
  - NM/PET
  - What MR-PET can offer for radiation oncology

- **17:15 - 18:15**
  - HONORARY MEMBERS LECTURES

- **18:15 - 19:15**
  - POSTER RECEPTION - POSTER AWARDS
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Teaching Lecture: Pitfalls and risks of standardisation in high-tech radiotherapy</td>
</tr>
<tr>
<td>08:40</td>
<td>Teaching Lecture: DNA repair and response for beginners</td>
</tr>
<tr>
<td>09:00</td>
<td>Teaching Lecture: Anal cancer: current guidelines and remaining questions</td>
</tr>
<tr>
<td>09:20</td>
<td>Teaching Lecture: Radiotherapy and immune-therapy on the biological basis</td>
</tr>
<tr>
<td>09:40</td>
<td>Teaching Lecture: Immunological importance of intratumoral brachytherapy: bronchus, oesophagus, prosstatic and hepatobiliary duct cancer</td>
</tr>
<tr>
<td>10:00</td>
<td>Teaching Lecture: Big data in radiotherapy</td>
</tr>
<tr>
<td>10:20</td>
<td>Teaching Lecture: The role of dosimetric audit in safety, quality and best practice for external beam and brachytherapy</td>
</tr>
<tr>
<td>10:40</td>
<td>Teaching Lecture: General introduction to head and neck radiotherapy</td>
</tr>
<tr>
<td>11:00</td>
<td>Teaching Lecture: e-Learning for Professionals in Radiotherapy: what, why and how</td>
</tr>
<tr>
<td>11:45</td>
<td>Symposium: Quality beyond accuracy: are we failing to see the forest for the trees?</td>
</tr>
<tr>
<td>12:05</td>
<td>Symposium: Targeting DNA repair / DDR pre-clinical evidence for treatment delivery: translational and clinical improvement</td>
</tr>
<tr>
<td>12:45</td>
<td>Symposium: Modern techniques for old indications: robotic surgery and brachytherapy</td>
</tr>
<tr>
<td>13:05</td>
<td>Symposium: New approaches in clinical trials: quantitative imaging to individualise radiotherapy</td>
</tr>
<tr>
<td>13:25</td>
<td>Symposium: How can clinical trials be used to improve threshold and outcome in radiotherapy</td>
</tr>
<tr>
<td>13:45</td>
<td>Symposium: What is the best for PBI: radical boost or fractionated BRT?</td>
</tr>
<tr>
<td>14:05</td>
<td>Symposium: Challenges of bowel cancer radiotherapy: the role of current clinical trials?</td>
</tr>
<tr>
<td>14:25</td>
<td>Symposium: DNA repair and response in rectal cancer: potential and challenges to preclude the use of current guidelines</td>
</tr>
<tr>
<td>14:45</td>
<td>Symposium: Radiotherapy of prostate cancer: technical challenges</td>
</tr>
<tr>
<td>15:05</td>
<td>Symposium: Results of phase I trial combining PARP inhibition and radiotherapy in multiple sites</td>
</tr>
<tr>
<td>15:25</td>
<td>Symposium: What are the implications of dose-volume effects in the treatment of prostate cancer?</td>
</tr>
<tr>
<td>15:45</td>
<td>Symposium: The role of imaging in determining dose-volume effects in prostate cancer: technical challenges</td>
</tr>
<tr>
<td>16:05</td>
<td>Symposium: The impact of radiotherapy on toxicity and outcomes in prostate cancer: technical challenges</td>
</tr>
<tr>
<td>16:25</td>
<td>Symposium: The potential of robotic surgery in prostate cancer: technical challenges</td>
</tr>
<tr>
<td>16:45</td>
<td>Symposium: The role of brachytherapy in the management of locally advanced prostate cancer: technical challenges</td>
</tr>
<tr>
<td>17:05</td>
<td>Symposium: Current clinical trials: a joint session of Young Radiation Oncology (YROG) and Young National Societies (YNOS) Round table with presenters</td>
</tr>
<tr>
<td>17:25</td>
<td>Symposium: Young Radiation Oncology: How to do a good manuscript and get it published</td>
</tr>
<tr>
<td>17:45</td>
<td>Symposium: The French Society of Young Radiation Oncology (SOFYORO) Young Report from the Young Radiation Oncology Group of EORTC (YRTOG) Group of EORTC professionals</td>
</tr>
<tr>
<td>18:05</td>
<td>Symposium: The role of radiation therapy in the treatment of rectal cancer: technical challenges</td>
</tr>
<tr>
<td>18:25</td>
<td>Symposium: The role of radiation therapy in the treatment of rectal cancer: technical challenges</td>
</tr>
<tr>
<td>18:45</td>
<td>Symposium: The role of radiation therapy in the treatment of rectal cancer: technical challenges</td>
</tr>
<tr>
<td>19:05</td>
<td>Symposium: The role of radiation therapy in the treatment of rectal cancer: technical challenges</td>
</tr>
</tbody>
</table>

**SUNDAY 1 MAY 2016**

**08:00 – 08:40**

- **TEACHING LECTURE**
  - Pitfalls and risks of standardisation in high-tech radiotherapy
  - DNA repair and response for beginners
  - Anal cancer: current guidelines and remaining questions
  - Radiotherapy and immune-therapy on the biological basis
  - Immunological importance of intratumoral brachytherapy: bronchus, oesophagus, prosstatic and hepatobiliary duct cancer
  - Big data in radiotherapy technology, challenges and opportunities
  - The role of dosimetric audit in safety, quality and best practice for external beam and brachytherapy
  - General introduction to head and neck radiotherapy
  - e-Learning for Professionals in Radiotherapy: what, why and how

**08:45 – 10:00**

- **SYMPOSIUM**
  - Quality beyond accuracy: are we failing to see the forest for the trees?
  - Targeting DNA repair / DDR pre-clinical evidence for treatment delivery: translational and clinical improvement
  - The potential of active particles in quality and safety in radiotherapy
  - Beyond accuracy how can clinical trials help improve treatment quality?

**10:00 – 10:30**

- **SYMPOSIUM**
  - New approaches in rectal cancer: how to deliver the CTV for rectal cancer? An international consensus
  - Modern techniques for old indications: robotic surgery and brachytherapy
  - how to individualise radiotherapy for head and neck cancer
  - How effective is current clinical practice in dealing with the QA in clinical trials?

**10:45 – 12:00**

- **SYMPOSIUM**
  - Targeting DNA repair / DDR pre-clinical evidence for treatment delivery: translational and clinical improvement
  - The potential of active particles in quality and safety in radiotherapy
  - Beyond accuracy how can clinical trials help improve treatment quality?

**12:00 – 12:45**

- **SYMPOSIUM**
  - Quality beyond accuracy: are we failing to see the forest for the trees?
  - Targeting DNA repair / DDR pre-clinical evidence for treatment delivery: translational and clinical improvement
  - The potential of active particles in quality and safety in radiotherapy
  - Beyond accuracy how can clinical trials help improve treatment quality?

**13:00 – 14:30**

- **SYMPOSIUM**
  - New approaches in rectal cancer: how to deliver the CTV for rectal cancer? An international consensus
  - Modern techniques for old indications: robotic surgery and brachytherapy
  - how to individualise radiotherapy for head and neck cancer
  - How effective is current clinical practice in dealing with the QA in clinical trials?

**14:30 – 15:45**

- **SYMPOSIUM**
  - Targeting DNA repair / DDR pre-clinical evidence for treatment delivery: translational and clinical improvement
  - The potential of active particles in quality and safety in radiotherapy
  - Beyond accuracy how can clinical trials help improve treatment quality?

**15:45 – 16:15**

- **SYMPOSIUM**
  - New approaches in rectal cancer: how to deliver the CTV for rectal cancer? An international consensus
  - Modern techniques for old indications: robotic surgery and brachytherapy
  - how to individualise radiotherapy for head and neck cancer
  - How effective is current clinical practice in dealing with the QA in clinical trials?

**16:15 – 17:15**

- **SYMPOSIUM**
  - Targeting DNA repair / DDR pre-clinical evidence for treatment delivery: translational and clinical improvement
  - The potential of active particles in quality and safety in radiotherapy
  - Beyond accuracy how can clinical trials help improve treatment quality?

**17:50 – 18:00**

- **COMPANY SPONSORED LECTURES**
  - Health Economics in Radiation Oncology (HERO)
  - Young reception and Report from the Young ESTRO Committee

**19:00**

- **SUPER BURI**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:40</td>
<td>How to bring QUANTEC into the 21st century? Shared decision making</td>
</tr>
<tr>
<td></td>
<td>Genetic mouse models for cancer research</td>
</tr>
<tr>
<td></td>
<td>SBRT for oligometastatic disease</td>
</tr>
<tr>
<td></td>
<td>Advanced treatment strategies for head and neck cancer</td>
</tr>
<tr>
<td></td>
<td>Dose to tumour vs. dose to tissues: issues for treatment planning and dose measurement</td>
</tr>
<tr>
<td></td>
<td>Nanodosimetry: from radiation physics to radiation biology</td>
</tr>
<tr>
<td></td>
<td>Brachytherapy for the prostate region, status and perspective for the future</td>
</tr>
<tr>
<td>08:45 - 10:00</td>
<td>Adaptive radiotherapy for coping with anatomical variations: hope or hype?</td>
</tr>
<tr>
<td></td>
<td>Overview of clinical practice of ART for abdominal and pelvic tumours.</td>
</tr>
<tr>
<td></td>
<td>The challenges of ART from a physicist’s perspective.</td>
</tr>
<tr>
<td></td>
<td>The practical “cost” of adaptive radiotherapy (in personnel time, patient time, etc.):</td>
</tr>
<tr>
<td></td>
<td>Time is not on our side: cardiovascular toxicity after radiotherapy.</td>
</tr>
<tr>
<td></td>
<td>The risk of cardiovascular disease after breast cancer treatment: the clinician’s point of view.</td>
</tr>
<tr>
<td></td>
<td>Predicting cardiac toxicity after breast irradiation: new quantitative data and new challenges.</td>
</tr>
<tr>
<td></td>
<td>Active surveillance for cardiovascular disease after head and neck cancers.</td>
</tr>
<tr>
<td></td>
<td>Emerging biomarkers: Circulating tumor cells as biomarkers for lung radiotherapy.</td>
</tr>
<tr>
<td></td>
<td>The fall and rise of H3AX as predictive biomarker for radiotherapy.</td>
</tr>
<tr>
<td></td>
<td>Protonic brachytherapy - the new prostate cancer treatment and its influence on treatment response.</td>
</tr>
<tr>
<td></td>
<td>SBRT for oligometastatic disease: Conditioning SBRT and immunotherapy: a promising approach?</td>
</tr>
<tr>
<td></td>
<td>SBRT for metastatic disease: how far can and should we go?</td>
</tr>
<tr>
<td></td>
<td>Abdominal-pelvic targets: are there any roles for ART?</td>
</tr>
<tr>
<td></td>
<td>Dose implications: ARtFORCE project</td>
</tr>
<tr>
<td></td>
<td>Modern ART based on functional / biological imaging</td>
</tr>
<tr>
<td></td>
<td>Fractional imaging for ART (biological base and potential impact on clinical outcomes).</td>
</tr>
<tr>
<td></td>
<td>Adaptive radiotherapy: the example of breast and head and neck cancer is there any role for ART?</td>
</tr>
<tr>
<td></td>
<td>Dose implications: secondary cancer risk: more from epidemiologic studies.</td>
</tr>
<tr>
<td></td>
<td>Modelling of secondary cancer and compound primary and secondary cancer risk in patients and sub-patients.</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Secondary cancer after radiotherapy: from cancer registries to clinical impacts</td>
</tr>
<tr>
<td></td>
<td>Secondary cancer risk: more from epidemiologic studies.</td>
</tr>
<tr>
<td></td>
<td>Modelling of secondary cancer risk: a case for ART.</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td>Modern SBRT based on functional / biological imaging.</td>
</tr>
<tr>
<td></td>
<td>Radiation biology: what do we really see?</td>
</tr>
<tr>
<td></td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td></td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td>11:30 - 13:00</td>
<td>Clinical implications of secondary cancer for PET to oncologists.</td>
</tr>
<tr>
<td></td>
<td>Clinical implications of secondary cancer risk in patients and sub-patients.</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>In room Adaptive Imaging with a focus on MIB-1</td>
</tr>
<tr>
<td></td>
<td>SBRT Linacs: physicist’s perspective</td>
</tr>
<tr>
<td></td>
<td>Adaptive planning, dose and verification with MRI-based radiotherapy.</td>
</tr>
<tr>
<td></td>
<td>Clinical experience with low-field MR-guided radiotherapy.</td>
</tr>
<tr>
<td></td>
<td>Linac-based MRI device.</td>
</tr>
<tr>
<td>14:30 - 16:00</td>
<td>Communication with patients: how do we really see?</td>
</tr>
<tr>
<td></td>
<td>Healthcare professionals’ perspectives</td>
</tr>
<tr>
<td></td>
<td>Radiation biology: new insights and new challenges.</td>
</tr>
<tr>
<td></td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td></td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td></td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td></td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td></td>
<td>Imaging biology: new insights and new challenges.</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>Dose implications: secondary cancer risk: more from epidemiologic studies.</td>
</tr>
<tr>
<td></td>
<td>Dose implications: secondary cancer risk: a case for ART.</td>
</tr>
<tr>
<td></td>
<td>Dose implications: secondary cancer risk: a case for ART.</td>
</tr>
<tr>
<td></td>
<td>Dose implications: secondary cancer risk: a case for ART.</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>General Assembly</td>
</tr>
<tr>
<td>20.00</td>
<td>Social Evening</td>
</tr>
</tbody>
</table>
TUESDAY 3 MAY 2016

08.50 - 09.10

The new ‘Io’ in radiation biology
Textures analysis of medical images
Heavy ion therapy: physical, radiobiological and clinical aspects
Neuroendocrine tumours – personalised diagnosis and treatment using radiolabelled peptides
Radiotherapy for paediatric brain tumours
Role and validation of deformable image registration in clinical practice
VMAT QA: To do and not to do, those are the questions
Optimising workflow in a radiotherapy department

09.15 – 10.30

SYMPOSIUM
New concepts of tumour radioresistance
The contribution of cancer stem cells to tumour radioresistance
Novel insights in relationship of bone and breast cancer
Towards Personalised Radiation Oncology (PRO)
The tumour in 3D: the role of tumour microenvironment
Relevance of 3D cultures to address radiation response and novel RT combination strategies
The potential of normal tissue organoids cultures
The impact of a novel 3D cell culture model of glioblastomas on radiation and drug radioresistance
Radiomics promotes immunological signature

SYMPOSIUM
WBRT for brain metastases - the end of an era?
Whole brain radiotherapy – the end of an era in NSCLC only or, is radio resistant still a challenge?
Focal radiotherapy for multiple brain metastases
Role of systemic therapy in the treatment of brain metastases
Radiotherapy "autoimmunization" with systemic immune modulators for modern immunotherapy
Should the combined treatment be part of our daily practice?
ART in particle therapy
The need for adaptive approaches in proton therapy compared to photons
Case driven CT as a tool for adaptive techniques in proton therapy
Adaptive techniques in proton therapy of the lung
Are we on the right track and adaptive particle therapy

10.30 – 11.00

COFFEE BREAK

11.00 - 12.00

SYMPOSIUM
Combining radiotherapy with molecular targeted agents: learning from successes and failures
Radiomics - the future of radiotherapy?
Getting Genomics, identifying molecular phenotypes by integrating radiomics and genomics data
ProCT heterogeneity quantification through machine analysis: potential role for prognostic and predictive models
The potential of radiomics for radiotherapy individualisation

SYMPOSIUM
Radiology of proton / carbon / heavy ions
Growth simulation, alterations to carbon ion and X radiation
Normal tissue response in particle therapy
Proton-based proton therapy studies

SYMPOSIUM
New insights in treating varicalived metastasis
Recent progress in interventional radiology
What are the limits of minimally invasive surgery?
How to optimise the cardiac potential of SBRT?

SYMPOSIUM
IMRT, the new standard in treatment of gynecological, lung and breast cancer?
Obstacles and opportunities in the use of IMRT as a standard technique for gynaecological cancers?
IMRT for lung cancer: current status and future developments
IMRT in breast cancer: dream or reality?

SYMPOSIUM
Optimising workflow in a radiotherapy department
Does lean management improve patient safety culture?
Development and leadership roles

SYMPOSIUM
Optimisation and automation of the daily workflow
Optimising workflow using a workflow management system
Does lean management improve patient safety culture?

12.00 – 13.00

CLOSING LECTURE
This house believes that IMRT hyper-fractionation will be the standard of care

13.00
CLOSING REMARKS